Product Description
a small molecule ghrelin receptor (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813110/)
Mechanisms of Action: GHRH Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Healthy Volunteers
Phase 1: Spinal Cord Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12614001122640 |
ACTRN12614001122640 | P1 |
Completed |
Spinal Cord Injuries |
2013-10-30 |
2024-08-29 |
Treatments |
|
NCT00527046 |
A257-102 | P2 |
Terminated |
Healthy Volunteers |
2001-10-01 |
2019-03-21 |
Treatments |